WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

safety and ease of administration of the rapid-acting insulin analogue insulin aspart in comparison with human insulin (HI) in diabetes mellitus in the following categories: (a) in adults ...

and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price will be reduced by 75%, making it the same ...

an older formulation of the Danish pharma's blockbuster insulin analogue product insulin aspart. Sanofi-Aventis' Merilog version of the product has been cleared for the treatment of adult and ...

Types of insulin include rapid-, regular-, intermediate-, and long-acting, based on how long they take to start working. You may take a combination of these when managing type 2 diabetes.

Rapid-acting insulin called insulin aspart - this lowers your blood sugar level soon after you inject it. Ryzodeg ® 70/30 is a modified insulin, also called an insulin analogue, which is similar ...

Thirty-seven-year-old Nupur Lalvani, who has been living with Type 1 diabetes since the age of eight, was dependent on ...

Rapid acting insulin called insulin aspart - this lowers your blood sugar soon after you inject it. Ryzodeg ® 70/30 is a modified insulin, also called an insulin analogue, which is similar to the ...

Potential Weakness: The potential weakness of the studies is that they were of relatively short duration (≤24 weeks) and so the long-term effects of insulin aspart in CSII cannot be assessed.